BeiGene Scores Label Expansion For Tevimbra In Frontline Esophageal Cancer

The company sees a potential billion-dollar market opportunity in its approved indications and is launching the drug in what an exec called “a very targeted fashion” at a recent conference.

BeiGene is expanding its presence in a market worth potentially $1bn or more with the US Food and Drug Administration approval of Tevimbra (tislelizumab-jsgr) for frontline esophageal cancer, where the company is aiming for a targeted launch approach in the US and EU in a field dominated by larger players.

The drug maker received FDA approval on 3 March for Tevimbra combined with platinum chemotherapy for first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) with PD-L1 expression of 1 or greater. The company plans to

Key Takeaways

The FDA approved BeiGene’s Tevimbra for frontline esophageal squamous cell carcinoma with PD-L1 expression of 1 or greater combined with chemotherapy.
The company sees the vast majority of patients with frontline ESCC as being potentially eligible for the drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

19 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

16 May 2025

• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

13 May 2025

• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

12 May 2025

• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.